Logo
x

Search category

Subscribe Now

PIK3CA mutation

Novartis's Solar-1 trial BYL719 (PI3Ki- alpelisib) meets primary endpoints in advanced or mBC patients

Novartis's Solar-1 trial BYL719 (PI3Ki- alpelisib) meets primary endpoints in advanced or mBC patients

  • August 24, 2018
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.